Tvardi Therapeutics, Inc. (TVRD)
0.8571
-0.01
(-0.86%)
USD |
NASDAQ |
Nov 06, 10:41
Tvardi Therapeutics Enterprise Value : -7.510M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -7.510M |
| November 04, 2026 | -7.539M |
| November 03, 2026 | -7.788M |
| November 02, 2026 | -8.065M |
| October 30, 2026 | -8.182M |
| October 29, 2026 | -7.524M |
| October 28, 2026 | -7.297M |
| October 27, 2026 | -7.502M |
| October 26, 2026 | -7.72M |
| October 23, 2026 | -6.802M |
| October 22, 2026 | -6.500M |
| October 21, 2026 | -6.051M |
| October 20, 2026 | -6.314M |
| October 19, 2026 | -6.520M |
| October 16, 2026 | -6.145M |
| October 15, 2026 | -5.582M |
| October 14, 2026 | -6.239M |
| October 13, 2026 | -5.863M |
| October 12, 2026 | -5.676M |
| October 09, 2026 | -5.957M |
| October 08, 2026 | -5.488M |
| October 07, 2026 | -5.301M |
| October 06, 2026 | -5.488M |
| October 05, 2026 | -4.925M |
| October 02, 2026 | -4.832M |
| Date | Value |
|---|---|
| October 01, 2026 | -3.987M |
| September 30, 2026 | -3.893M |
| September 29, 2026 | -3.612M |
| September 28, 2026 | -3.143M |
| September 25, 2026 | -3.706M |
| September 24, 2026 | -5.676M |
| September 23, 2026 | -3.237M |
| September 22, 2026 | -0.8914M |
| September 21, 2026 | -0.5161M |
| September 18, 2026 | -0.3285M |
| September 17, 2026 | -0.4223M |
| September 16, 2026 | 0.6096M |
| September 15, 2026 | 0.8911M |
| September 14, 2026 | 1.548M |
| September 11, 2026 | 1.923M |
| September 10, 2026 | 1.595M |
| September 09, 2026 | 1.735M |
| September 08, 2026 | 2.580M |
| September 04, 2026 | 2.298M |
| September 03, 2026 | 1.735M |
| September 02, 2026 | 2.017M |
| September 01, 2026 | 0.7504M |
| August 31, 2026 | 1.266M |
| August 28, 2026 | 1.454M |
| August 27, 2026 | 1.266M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.834B |
| Corcept Therapeutics, Inc. | 7.472B |
| Veru, Inc. | 12.02M |
| Johnson & Johnson | 682.93B |
| Eli Lilly & Co. | 1.329T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.457M |
| Total Expenses (Quarterly) | 6.457M |
| EPS Diluted (Quarterly) | -0.6883 |
| Earnings Yield | -324.2% |
| Normalized Earnings Yield | -324.17 |